vTv Therapeutics Inc (VTVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has a cash flow conversion efficiency ratio of 0.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.15 Million) by net assets ($89.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VTVT net asset quality score to measure how much of total assets are equity-financed.
vTv Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how vTv Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of vTv Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
vTv Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of vTv Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhong Yang Technology Co Ltd
TW:6668
|
-0.018x |
|
Megaforce Co Ltd
TWO:3294
|
0.065x |
|
Servotronics Inc
NYSE MKT:SVT
|
-0.067x |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
0.037x |
|
Torimbia Socimi S.A.
MC:YTRM
|
0.191x |
|
Nelly Group AB
ST:NELLY
|
-0.064x |
|
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
|
-0.120x |
|
Dongsung Corporation
KO:102260
|
-0.005x |
Annual Cash Flow Conversion Efficiency for vTv Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of vTv Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of vTv Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.44 Million | $-25.25 Million | -0.392x | +77.85% |
| 2024-12-31 | $14.30 Million | $-25.31 Million | -1.770x | -272.03% |
| 2023-12-31 | $-18.55 Million | $-19.08 Million | 1.029x | +139.40% |
| 2022-12-31 | $5.84 Million | $-15.25 Million | -2.611x | -105.85% |
| 2021-12-31 | $15.22 Million | $-19.31 Million | -1.268x | +73.27% |
| 2020-12-31 | $3.79 Million | $-18.00 Million | -4.746x | -282.25% |
| 2019-12-31 | $-8.84 Million | $-23.02 Million | 2.604x | +703.31% |
| 2018-12-31 | $-82.85 Million | $-26.86 Million | 0.324x | +9.88% |
| 2017-12-31 | $-151.05 Million | $-44.56 Million | 0.295x | -44.35% |
| 2016-12-31 | $-90.94 Million | $-48.21 Million | 0.530x | +11.87% |
| 2015-12-31 | $-77.97 Million | $-36.95 Million | 0.474x | +667.92% |
| 2014-12-31 | $-498.81 Million | $-30.78 Million | 0.062x | -55.04% |
| 2013-12-31 | $-303.73 Million | $-41.68 Million | 0.137x | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more